Nektar Therapeutics (NKTR) Cash from Financing Activities (2010 - 2026)

Nektar Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $529.5 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 7564885.71% year-over-year to $529.5 million; the TTM figure through Mar 2026 stood at $710.1 million (up 581955.74% YoY), while the FY2025 annual figure was $180.6 million, up 328.71% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $529.5 million, up from $38.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $529.5 million in Q1 2026, with the low at $7000.0 in Q1 2025.
• The 5-year median for Cash from Financing Activities is $157000.0 (2022), against an average of $53.8 million.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities tumbled 99.98% in 2025, then soared 7564885.71% in 2026.
• Nektar Therapeutics' Cash from Financing Activities stood at $103000.0 in 2022, then tumbled by 88.35% to $12000.0 in 2023, then soared by 591.67% to $83000.0 in 2024, then surged by 46491.57% to $38.7 million in 2025, then soared by 1269.37% to $529.5 million in 2026.
• Business Quant data shows NKTR's Cash from Financing Activities at $529.5 million in Q1 2026, $38.7 million in Q4 2025, and $141.7 million in Q3 2025.